Michihiro Mutoh Selected Research

nitrosobis(2-oxopropyl)amine (NBOP)

5/2021	Effect of Fucoxanthinol on Pancreatic Ductal Adenocarcinoma Cells from an N-Nitrosobis(2-oxopropyl)amine-initiated Syrian Golden Hamster Pancreatic Carcinogenesis Model.
10/2018	Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans.
3/2013	Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.
5/2012	In vivo SPECT imaging with 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model.
2/2011	Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease.
7/2010	Imaging study of pancreatic ductal adenocarcinomas in Syrian hamsters using X-ray micro-computed tomography (CT).
10/2007	Enhanced thyroid carcinogenicity of N-nitrosobis(2-oxopropyl)amine in Otsuka Long-Evans Tokushima Fatty rats, a model of type II diabetes mellitus.
8/2007	Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michihiro Mutoh Research Topics

Disease

62	Neoplasms (Cancer) 01/2022 - 01/2002
47	Carcinogenesis 01/2022 - 01/2002
37	Colorectal Neoplasms (Colorectal Cancer) 07/2022 - 03/2006
25	Intestinal Polyps 03/2022 - 02/2005
24	Colonic Neoplasms (Colon Cancer) 03/2022 - 01/2002
19	Polyps 03/2022 - 03/2006
15	Adenocarcinoma 01/2022 - 05/2005
15	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 08/2007
8	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 03/2022 - 04/2008
8	Inflammation (Inflammations) 01/2021 - 01/2006
8	Adenoma (Adenomas) 04/2018 - 12/2006
8	Hyperlipidemias (Hyperlipidemia) 03/2013 - 02/2005
7	Aberrant Crypt Foci 08/2017 - 01/2002
6	Body Weight (Weight, Body) 07/2021 - 10/2006
5	Obesity 07/2021 - 08/2011
3	Carcinoma (Carcinomatosis) 10/2006 - 04/2002
2	Hypoxia (Hypoxemia) 01/2019 - 01/2018
2	Lung Neoplasms (Lung Cancer) 01/2017 - 08/2015
2	Hypertriglyceridemia 01/2016 - 04/2008
2	Hyperplasia 08/2013 - 08/2008
2	Type 2 Diabetes Mellitus (MODY) 07/2013 - 10/2007

Drug/Important Bio-Agent (IBA)

20	Messenger RNA (mRNA)IBA 04/2020 - 01/2002
17	fucoxanthinIBA 01/2022 - 07/2017
15	AzoxymethaneIBA 01/2022 - 01/2002
13	fucoxanthinolIBA 07/2022 - 07/2017
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2002
10	LipidsIBA 07/2017 - 02/2005
9	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 03/2022 - 01/2002
8	nitrosobis(2-oxopropyl)amine (NBOP)IBA 05/2021 - 08/2007
8	Triglycerides (Triacylglycerol)IBA 01/2012 - 04/2006
7	colibactinIBA 03/2022 - 01/2019
7	AdipokinesIBA 10/2018 - 04/2008
6	Carotenoids (Carotene)IBA 07/2022 - 12/2019
6	Pharmaceutical PreparationsIBA 11/2021 - 01/2005
6	CarcinogensIBA 01/2019 - 01/2002
6	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 11/2015 - 03/2002
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2022 - 02/2013
5	LigandsIBA 12/2021 - 08/2007
5	Glycine (Aminoacetic Acid)FDA LinkGeneric 11/2020 - 01/2018
5	Interleukin-6 (Interleukin 6)IBA 04/2020 - 01/2012
5	CateninsIBA 04/2017 - 07/2013
5	ProstaglandinsIBA 03/2014 - 01/2002
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2012 - 02/2005
4	ChloridesIBA 07/2022 - 01/2005
4	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2022 - 12/2019
4	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2012 - 02/2005
4	PPAR gammaIBA 01/2012 - 02/2005
4	Prostaglandins EIBA 03/2007 - 01/2002
4	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2006 - 01/2002
3	Cyclin D1IBA 03/2022 - 04/2017
3	Mesalamine (Mesalazine)FDA LinkGeneric 03/2022 - 01/2019
3	Dextrans (Dextran)FDA Link 01/2022 - 11/2020
3	Insulin (Novolin)FDA Link 07/2021 - 01/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 11/2015
3	EnzymesIBA 11/2019 - 01/2012
3	LeptinIBA 01/2016 - 08/2011
3	Biological ProductsIBA 07/2015 - 04/2002
3	Urethane (Ethyl Carbamate)IBA 08/2013 - 09/2008
3	Indomethacin (Indometacin)FDA LinkGeneric 11/2012 - 10/2007
3	4- diethoxyphosphorylmethyl- N- (4- bromo- 2- cyanophenyl)benzamideIBA 01/2012 - 02/2005
3	Pioglitazone (Actos)FDA Link 01/2012 - 04/2006
3	PPAR alphaIBA 10/2007 - 02/2005
2	MutagensIBA 01/2022 - 01/2020
2	XanthophyllsIBA 01/2022 - 10/2017
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	CC ChemokinesIBA 01/2022 - 12/2021
2	PolyketidesIBA 01/2022 - 01/2020
2	Dietary CalciumIBA 07/2021 - 09/2013
2	SuspensionsIBA 01/2021 - 01/2019
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2020 - 07/2015
2	AntioxidantsIBA 01/2020 - 11/2019
2	IntegrinsIBA 12/2019 - 08/2013
2	LuciferasesIBA 11/2019 - 08/2017
2	Transcription Factors (Transcription Factor)IBA 11/2019 - 08/2017
2	NF-kappa B (NF-kB)IBA 01/2019 - 10/2003
2	IsothiocyanatesIBA 01/2019 - 01/2017
2	CholesterolIBA 01/2019 - 04/2006
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 08/2017 - 05/2017
2	TCF Transcription FactorsIBA 04/2017 - 07/2015
2	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2015 - 03/2015
2	sesamolIBA 03/2015 - 03/2014
2	Plasminogen Activator Inhibitor 1IBA 01/2014 - 04/2008
2	AcidsIBA 08/2013 - 05/2012
2	cyclo(arginylglycyl)IBA 08/2013 - 05/2012
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 08/2013 - 05/2012
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2011 - 04/2008
2	HeptanesIBA 08/2008 - 03/2006
2	7- chloro- 3- imino- 5- methyl- 2- azabicyclo(4.1.0)heptaneIBA 08/2008 - 03/2006
2	Dinoprostone (PGE2)FDA Link 03/2007 - 01/2006
2	ONO 8711IBA 03/2007 - 05/2005
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2006 - 10/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2005 - 01/2005
1	Sodium Salicylate (Salicylate, Sodium)IBA 03/2022
1	Polyketide SynthasesIBA 01/2022
1	Cadherins (E-Cadherin)IBA 12/2021

Therapy/Procedure

9	Chemoprevention 01/2022 - 01/2006
4	Colectomy 01/2021 - 01/2016
3	Therapeutics 01/2012 - 01/2005
2	Pancreaticoduodenectomy 10/2016 - 03/2014
2	Intraperitoneal Injections 08/2013 - 11/2012